11

Sep2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2017:        47 negotiations are currently underway with 6 new files added since the last update of July 31, 2017: Brilinta (ticagrelor): Used with ASA to prevent atherothrombotic events with history ... Read More

09

Aug2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2017:  46 negotiations are currently underway with 7 new files added since the last update of June 30, 2017: Cinqair (reslizumab): Used to treat severe eosinophilic asthma Giotrif (afatinib): Used to ... Read More

11

Jul2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2017: 42 negotiations are currently underway with 6 new files added since the last update of May 31, 2017: Caprelsa (vandetanib): Used to treat medullary thyroid cancer Kyprolis (carfilzomib): Used to ... Read More

15

Jun2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of May 31, 2017: 43 negotiations are currently underway with 9 new files added since the last update of April 30, 2017: Brivlera (brivarcetam): Used to treat partial-onset seizures Butrans (buprenorphine): Used to treat ... Read More

16

May2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2017: 38 negotiations are currently underway with 9 new files added since the last update of March 31, 2017: Cosentyx (secukinumab): Use to treat psoriatic arthritis Cosentyx (secukinumab): Used to treat ... Read More

13

Apr2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2017: 30 negotiations are currently underway with 3 new files added since the last update of February 28, 2017: Votrient (pazopanib hydrochloride): Used to treat genitourinary metastatic renal cell carcinoma Campral ... Read More

16

Mar2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of February 28, 2017: 33 negotiations are currently underway with 2 new files added since the last update of January 31, 2017: Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein ... Read More

28

Nov2016
Effective November 30, 2016, the Ontario Public Drug Programs will begin funding INFLECTRA™ (infliximab) as a limited use benefit for the following new indications: LU Code 477 - For the treatment of ulcerative colitis in patients who meet clinical criteria. LU Code 478 - For the treatment of moderate to severe Crohn’s ... Read More

13

Oct2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2016: 37 negotiations are currently underway with no new files added since the last update of August 31, 2016. 118 joint negotiations have been completed with 4 files successfully negotiated ... Read More

08

Sep2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2016: 40 negotiations are currently underway with 10 files added since the last update of July 31, 2016: Cotellic (cobimetinib): used to treat metastatic melanoma Fabrazyme (agalsidase beta): used to treat ... Read More